Showing 1 - 10 of 4,183
Persistent link: https://www.econbiz.de/10015357201
Persistent link: https://www.econbiz.de/10015357671
Persistent link: https://www.econbiz.de/10015357789
Background Adverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an eco‑ nomic issue with significant costs. Because they often occur during hospital stays, it is necessary to accurately quantify the costs of ADEs. This review aimed to investigate...
Persistent link: https://www.econbiz.de/10015358196
Background Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease. The economic burden of MS is substantial, and the high cost of Disease-modifying drugs (DMDs) prices are the main drivers of healthcare expenditures. We conducted a systematic review of studies evaluating the...
Persistent link: https://www.econbiz.de/10015358197
Background Time preferences for preventive behavior under novel risks and uncertain contexts may differ from timing preferences related to familiar risks. Therefore, it is crucial to examine drivers of preventative health behavior timing in light of new health risks. Using the case of COVID-19,...
Persistent link: https://www.econbiz.de/10015358199
Background Based on the legal framework laid down in section 130b (9) of Book V of the German Social Code, various criteria are relevant for the negotiated price for new patented drugs in Germany. European reference prices (ERPs) are one criterion. The ERP is based on the ex-factory prices...
Persistent link: https://www.econbiz.de/10015358230
There are no standards in diagnostic and therapeutic approaches to eye care in incomplete eyelid closure due to unresolved facial palsy (FP). Loading of the upper eyelid (UELL) with gold weights (GWs) or platinum chains (PCs) is a highly effective procedure for the correction of lagophthalmos....
Persistent link: https://www.econbiz.de/10015358241
Background Rare diseases pose immense challenges for healthcare systems due to their low prevalence, associated disabilities, and attendant treatment costs. Advancements in gene therapy, such as treatments for Spinal Muscular Atrophy (SMA), have introduced novel therapeutic options, but the high...
Persistent link: https://www.econbiz.de/10015358269
Background The European-wide statistics show that the use of flu vaccination remains low and the differences between countries are significant, as are those between different population groups within each country. Considerable research has focused on explaining vaccination uptake in relation to...
Persistent link: https://www.econbiz.de/10015358341